Literature DB >> 24916909

Can response-adaptive randomization increase participation in acute stroke trials?

Jason S Tehranisa1, William J Meurer2.   

Abstract

BACKGROUND AND
PURPOSE: A response-adaptive randomization (RAR) trial design actively adjusts the ratio of participants assigned to each trial arm, favoring the better performing treatment by using outcome data from participants already in the trial. Compared with a standard clinical trial, an RAR study design has the potential to improve patient participation in acute stroke trials.
METHODS: This cross-sectional randomized survey included adult emergency department patients, age≥18, without symptoms of stroke or other critical illness. A standardized protocol was used, and subjects were randomized to either an RAR or standard hypothetical acute stroke trial. After viewing the video describing the hypothetical trial (http://youtu.be/cKIWduCaPZc), reviewing the consent form, and having questions answered, subjects indicated whether they would consent to the trial. A multivariable logistic regression model was fitted to estimate the impact of RAR while controlling for demographic factors and patient understanding of the design.
RESULTS: A total of 418 subjects (210 standard and 208 RAR) were enrolled. All baseline characteristics were balanced between groups. There was significantly higher participation in the RAR trial (67.3%) versus the standard trial (54.5%), absolute increase: 12.8% (95% confidence interval, 3.7-22.2). The RAR group had a higher odds ratio of agreeing to research (odds ratio, 1.89; 95% confidence interval, 1.2-2.9) while adjusting for patient level factors. Trial designs were generally well understood by the participants.
CONCLUSIONS: The hypothetical RAR trial attracted more research participation than standard randomization. RAR has the potential to increase recruitment and offer benefit to future trial participants.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  cerebrovascular accident, acute; emergency medicine; stroke, acute; tissue plasminogen activator

Mesh:

Year:  2014        PMID: 24916909      PMCID: PMC4081030          DOI: 10.1161/STROKEAHA.114.005418

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  8 in total

1.  Covariate-adjusted response-adaptive designs for binary response.

Authors:  W F Rosenberger; A N Vidyashankar; D K Agarwal
Journal:  J Biopharm Stat       Date:  2001-11       Impact factor: 1.051

2.  An urn based covariate adjusted response adaptive allocation design.

Authors:  Uttam Bandyopadhyay; Rahul Bhattacharya
Journal:  Stat Methods Med Res       Date:  2012-01-26       Impact factor: 3.021

3.  Adaptive clinical trials: a partial remedy for the therapeutic misconception?

Authors:  William J Meurer; Roger J Lewis; Donald A Berry
Journal:  JAMA       Date:  2012-06-13       Impact factor: 56.272

4.  Proxies' decisions about clinical research participation for their charges.

Authors:  H L Muncie; J Magaziner; J R Hebel; J W Warren
Journal:  J Am Geriatr Soc       Date:  1997-08       Impact factor: 5.562

5.  Who will consent to emergency treatment trials for subarachnoid hemorrhage?

Authors:  Angela Del Giudice; Justin Plaum; Eileen Maloney; Scott E Kasner; Peter D Le Roux; Jill M Baren
Journal:  Acad Emerg Med       Date:  2009-03-06       Impact factor: 3.451

6.  Lay conceptions of the ethical and scientific justifications for random allocation in clinical trials.

Authors:  Elizabeth J Robinson; Cicely Kerr; Andrew Stevens; Richard Lilford; David Braunholtz; Sarah Edwards
Journal:  Soc Sci Med       Date:  2004-02       Impact factor: 4.634

7.  Who will participate in acute stroke trials?

Authors:  S E Kasner; A Del Giudice; S Rosenberg; M Sheen; J M Luciano; B L Cucchiara; S R Messé; L H Sansing; J M Baren
Journal:  Neurology       Date:  2009-05-12       Impact factor: 9.910

8.  Challenges in enrollment of minority, pediatric, and geriatric patients in emergency and acute care clinical research.

Authors:  Seth W Glickman; Kevin J Anstrom; Li Lin; Abhinav Chandra; Daniel T Laskowitz; Christopher W Woods; Debra H Freeman; Monica Kraft; Laura M Beskow; Kevin P Weinfurt; Kevin A Schulman; Charles B Cairns
Journal:  Ann Emerg Med       Date:  2008-01-11       Impact factor: 5.721

  8 in total
  6 in total

1.  Are outcome-adaptive allocation trials ethical?

Authors:  Spencer Phillips Hey; Jonathan Kimmelman
Journal:  Clin Trials       Date:  2015-02-03       Impact factor: 2.486

Review 2.  Strategies to improve recruitment to randomised trials.

Authors:  Shaun Treweek; Marie Pitkethly; Jonathan Cook; Cynthia Fraser; Elizabeth Mitchell; Frank Sullivan; Catherine Jackson; Tyna K Taskila; Heidi Gardner
Journal:  Cochrane Database Syst Rev       Date:  2018-02-22

3.  Clinical trialist perspectives on the ethics of adaptive clinical trials: a mixed-methods analysis.

Authors:  Laurie J Legocki; William J Meurer; Shirley Frederiksen; Roger J Lewis; Valerie L Durkalski; Donald A Berry; William G Barsan; Michael D Fetters
Journal:  BMC Med Ethics       Date:  2015-05-03       Impact factor: 2.652

4.  A Research Agenda for Precision Medicine in Sepsis and Acute Respiratory Distress Syndrome: An Official American Thoracic Society Research Statement.

Authors:  Faraaz Ali Shah; Nuala J Meyer; Derek C Angus; Rana Awdish; Élie Azoulay; Carolyn S Calfee; Gilles Clermont; Anthony C Gordon; Arthur Kwizera; Aleksandra Leligdowicz; John C Marshall; Carmen Mikacenic; Pratik Sinha; Balasubramanian Venkatesh; Hector R Wong; Fernando G Zampieri; Sachin Yende
Journal:  Am J Respir Crit Care Med       Date:  2021-10-15       Impact factor: 30.528

5.  Should RECOVERY have used response adaptive randomisation? Evidence from a simulation study.

Authors:  Tamir Sirkis; Benjamin Jones; Jack Bowden
Journal:  BMC Med Res Methodol       Date:  2022-08-06       Impact factor: 4.612

6.  Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs.

Authors:  Thomas Burnett; Pavel Mozgunov; Philip Pallmann; Sofia S Villar; Graham M Wheeler; Thomas Jaki
Journal:  BMC Med       Date:  2020-11-19       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.